Short Interest in Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Decreases By 9.6%

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) was the recipient of a large decline in short interest in the month of August. As of August 31st, there was short interest totalling 1,107,000 shares, a decline of 9.6% from the August 15th total of 1,224,400 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is presently 11,070.0 days.

Swedish Orphan Biovitrum AB (publ) Stock Performance

OTCMKTS:BIOVF remained flat at $31.28 on Tuesday. Swedish Orphan Biovitrum AB has a 1-year low of $18.58 and a 1-year high of $31.28. The stock’s fifty day moving average price is $26.75 and its two-hundred day moving average price is $26.05. The company has a market capitalization of $9.23 billion, a P/E ratio of 52.13 and a beta of 0.59. The company has a debt-to-equity ratio of 0.32, a current ratio of 0.71 and a quick ratio of 0.50.

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) last issued its quarterly earnings data on Tuesday, July 16th. The company reported $0.07 earnings per share (EPS) for the quarter. Swedish Orphan Biovitrum AB (publ) had a net margin of 9.10% and a return on equity of 7.00%. The firm had revenue of $509.05 million for the quarter.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.